Topol E J, Califf R M, George B S, Kereiakes D J, Rothbaum D, Candela R J, Abbotsmith C W, Pinkerton C A, Stump D C, Collen D
Department of Internal Medicine, University of Michigan, Ann Arbor.
Circulation. 1988 May;77(5):1100-7. doi: 10.1161/01.cir.77.5.1100.
To determine whether tissue-type plasminogen activator (t-PA) and urokinase (UK) act synergistically to achieve coronary thrombolysis, incremental doses of both drugs were infused intravenously over 60 min. In 146 consecutive patients treated 3.0 +/- 1.0 hr from symptom onset, coronary angiography was performed 90 min after the start of the infusion and at 7 days. The groups of patients treated by different dose regimen were as follows: group I, 14 patients treated with t-PA 25 mg and UK 0.5 million U; group II, 20 patients given t-PA 25 mg and UK 1.0 million U; group III, 24 patients given t-PA 1.0 mg/kg and UK 0.5 million U; group IV, 33 patients treated with t-PA 1.0 mg/kg and UK 1.0 million U; and group V, 55 patients given t-PA 1.0 mg/kg and UK 2.0 million U. In groups I and II, patency of the infarct-related vessel at 90 min was only 36% and 42%, respectively. With 1 mg/kg t-PA and increasing doses of UK (groups III to V), patency ranged from 72% to 75% (overall 73%). Repeat catheterization at 7 days demonstrated reocclusion in groups III to V in 10 of 110 (9%). The patency and reocclusion rates in groups III to V were not significantly different from those in our previous study of 386 patients treated with t-PA alone (150 mg over 6 to 8 hr). In that study the patency rate of the infarct-related vessel at 90 min was 75% (p = .66) and reocclusion occurred in 15% (p = .11).(ABSTRACT TRUNCATED AT 250 WORDS)
为确定组织型纤溶酶原激活剂(t-PA)与尿激酶(UK)是否协同作用以实现冠状动脉溶栓,两种药物的递增剂量在60分钟内静脉输注。在症状发作后3.0±1.0小时接受治疗的146例连续患者中,输注开始90分钟后及7天时进行冠状动脉造影。不同剂量方案治疗的患者组如下:I组,14例患者接受25毫克t-PA和50万单位UK治疗;II组,20例患者给予25毫克t-PA和100万单位UK;III组,24例患者给予1.0毫克/千克t-PA和50万单位UK;IV组,33例患者接受1.0毫克/千克t-PA和100万单位UK治疗;V组,55例患者给予1.0毫克/千克t-PA和200万单位UK。在I组和II组中,90分钟时梗死相关血管的通畅率分别仅为36%和42%。使用1毫克/千克t-PA和递增剂量的UK(III组至V组),通畅率在72%至75%之间(总体为73%)。7天时重复导管插入术显示,III组至V组中110例中有10例(9%)再次闭塞。III组至V组的通畅率和再闭塞率与我们之前对386例单独接受t-PA治疗(6至8小时内给予150毫克)患者的研究结果无显著差异。在该研究中,90分钟时梗死相关血管的通畅率为75%(p = 0.66),再闭塞发生率为15%(p = 0.11)。(摘要截取自250字)